Cidara Net Working Capital from 2010 to 2024

CDTX Stock  USD 19.59  0.90  4.82%   
Cidara Therapeutics Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital is likely to outpace its year average in 2024. During the period from 2010 to 2024, Cidara Therapeutics Net Working Capital regression line of annual values had r-squared of  0.77 and arithmetic mean of  45,077,610. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
-6.6 M
Current Value
-6.2 M
Quarterly Volatility
27.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cidara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cidara Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 210.4 K, Selling General Administrative of 14 M or Other Operating Expenses of 63.2 M, as well as many indicators such as Price To Sales Ratio of 1.03, Dividend Yield of 0.0 or Days Sales Outstanding of 111. Cidara financial statements analysis is a perfect complement when working with Cidara Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cidara Therapeutics Correlation against competitors.
For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

Latest Cidara Therapeutics' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Cidara Therapeutics over the last few years. It is Cidara Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cidara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Cidara Net Working Capital Regression Statistics

Arithmetic Mean45,077,610
Geometric Mean36,765,172
Coefficient Of Variation60.91
Mean Deviation23,495,801
Median65,585,000
Standard Deviation27,455,445
Sample Variance753.8T
Range72.1M
R-Value(0.88)
Mean Square Error186.4T
R-Squared0.77
Significance0.000017
Slope(5,388,286)
Total Sum of Squares10553.2T

Cidara Net Working Capital History

2024-6.2 M
2023-6.6 M
202215.1 M
202137.7 M
202018.6 M
201935.6 M
201857.2 M

About Cidara Therapeutics Financial Statements

Cidara Therapeutics investors use historical fundamental indicators, such as Cidara Therapeutics' Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cidara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital-6.6 M-6.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.